Tarsus Pharmaceuticals (TARS) Stock Forecast: What Could Drive It in 2026
Short answer
What is actually driving Tarsus Pharmaceuticals (TARS) right now is XDEMVY prescription growth: XDEMVY net product sales rose more than 85% year over year in Q1 2026 to about $145 million, driven by expanding prescriber adoption and direct-to-consumer campaigns. Revenue (TTM) is ~$540M. If that keeps playing out, the setup is favourable; the risk to it is the overwhelming risk is single-product concentration: essentially all revenue comes from XDEMVY, so any slowdown in prescriptions, coverage, or pricing hits the whole company. No one can predict where TARS trades, and Walnut does not publish targets, so treat this as a scenario, not a price target or prediction.
What could drive Tarsus Pharmaceuticals (TARS) higher?
1. XDEMVY prescription growth
XDEMVY net product sales rose more than 85% year over year in Q1 2026 to about $145 million, driven by expanding prescriber adoption and direct-to-consumer campaigns. Management reaffirmed full-year 2026 guidance of roughly $670 to $700 million in net product sales. The core question is how long high double-digit growth can persist as the easiest-to-reach prescribers are converted.
2. Large, under-penetrated indication
Demodex blepharitis is estimated to affect tens of millions of Americans, and XDEMVY remains the only FDA-approved therapy that targets the underlying mites. Tarsus frames a path to more than $2 billion in peak sales on the back of that penetration runway. A short-seller has publicly disputed the size of the realistic addressable market, so this driver is also contested.
3. High-margin economics
XDEMVY carries gross margins around 93%, and the Q1 2026 net loss narrowed sharply to about $7 million from roughly $25 million a year earlier as revenue scaled against a largely fixed commercial base. If growth continues without a matching rise in selling and marketing spend, operating leverage could push the company toward sustained profitability.
4. Pipeline optionality
Beyond XDEMVY, Tarsus is advancing TP-04 for ocular rosacea and TP-05, an oral tablet studied for Lyme disease prevention, both using the same lotilaner molecule. Topline data for these Phase 2 programs is expected in the first half of 2027. Success would diversify a currently one-product company, though these are early-stage and carry standard clinical risk.
What could weigh on TARS?
The overwhelming risk is single-product concentration: essentially all revenue comes from XDEMVY, so any slowdown in prescriptions, coverage, or pricing hits the whole company. In late June 2026, short-seller Culper Research alleged that XDEMVY sales depend on donations routed to a blepharitis copay fund in a way it argues may violate the federal Anti-Kickback Statute, and it claimed the true addressable market is roughly a fifth of company estimates; these are unproven allegations, but they introduce regulatory, reimbursement, and reputational uncertainty. Tarsus also depends on intellectual property licensed from Elanco, faces gross-to-net and Medicare Part D dynamics that can compress net pricing, and still runs near breakeven with a history of losses. Cheaper off-label alternatives and potential future competitors, plus binary Phase 2 pipeline readouts, round out the risk set.
Where TARS trades today
A forecast starts from where the stock actually is. These are TARS's current figures, not a projection: the drivers and risks above are what would move them.
Snapshot for TARS as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
How to think about a TARS forecast
Rather than chasing a price target, it tends to help to weigh the drivers above against the risks, decide how long you are willing to hold, and size the position so a wrong call is survivable. A “forecast” is really a probability-weighted view of those drivers playing out, not a number.
For the full picture, see the TARS guide and whether TARS is a buy. In Walnut you can pressure-test the thesis against your real portfolio.
The bottom line on the TARS outlook
The bottom line: what is driving Tarsus Pharmaceuticals (TARS) is XDEMVY prescription growth, with revenue (ttm) at ~$540M. If that keeps playing out the setup is favourable; the risk is the overwhelming risk is single-product concentration: essentially all revenue comes from XDEMVY, so any slowdown in prescriptions, coverage, or pricing hits the whole company. No one can predict the price, so treat any TARS forecast as a scenario, not a target or prediction, and decide from your own thesis and time horizon. Walnut is not an investment adviser.
Build a basket around TARS with Walnut
Use Tarsus Pharmaceuticals as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
What is the forecast for Tarsus Pharmaceuticals (TARS)?
+
No one can reliably predict where TARS will trade, and Walnut does not publish price targets. What is more useful is the setup: the drivers that could push Tarsus Pharmaceuticals higher and the risks that could weigh on it. This page lays out both so you can form your own view. Not a recommendation.
What could drive TARS higher?
+
The main growth drivers are XDEMVY prescription growth; Large, under-penetrated indication; High-margin economics. Whether they play out is the real question, not a guaranteed path.
What are the risks to TARS?
+
The overwhelming risk is single-product concentration: essentially all revenue comes from XDEMVY, so any slowdown in prescriptions, coverage, or pricing hits the whole company. In late June 2026, short-seller Culper Research alleged that XDEMVY sales depend on donations routed to a blepharitis copay fund in a way it argues may violate the federal Anti-Kickback Statute, and it claimed the true addressable market is roughly a fifth of company estimates; these are unproven allegations, but they introduce regulatory, reimbursement, and reputational uncertainty. Tarsus also depends on intellectual property licensed from Elanco, faces gross-to-net and Medicare Part D dynamics that can compress net pricing, and still runs near breakeven with a history of losses. Cheaper off-label alternatives and potential future competitors, plus binary Phase 2 pipeline readouts, round out the risk set.
Will TARS stock go up in 2026?
+
Nobody knows, and anyone who says they do is guessing. Tarsus Pharmaceuticals's direction depends on whether the drivers above outweigh the risks, plus the broader market. Focus on the thesis and your time horizon rather than a single-year call.
Is TARS a buy?
+
That depends on your thesis, time horizon, and what you already own, not on a forecast. See the TARS "is it a buy?" page for a framework. Walnut is not an investment adviser.
Walnut is informational, not investment advice. This page describes drivers and risks; it is not a price forecast, target, or recommendation. Markets are uncertain and past performance does not predict future results.